Get the Stockscreener App
123.43
0.06%
0.07
Nuvalent Inc stock is traded at $123.43, with a volume of 4.47M.
It is up +0.06% in the last 24 hours and up +23.55% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$123.36
Open:
$123.4
24h Volume:
4.47M
Relative Volume:
2.35
Market Cap:
$9.77B
Revenue:
-
Net Income/Loss:
$-450.07M
P/E Ratio:
-20.37
EPS:
-6.0583
Net Cash Flow:
$-312.79M
1W Performance:
-0.02%
1M Performance:
+23.55%
6M Performance:
+21.71%
1Y Performance:
+63.42%
1-Day Range:
$123.30
$123.56
1-Week Range:
$123.16
$123.56
52-Week Range:
$71.13
$123.62
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
123.43 | 9.77B | 0 | -450.07M | -312.79M | -6.0583 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-26 | Initiated | Wells Fargo | Overweight |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-12-25 | Initiated | Canaccord Genuity | Buy |
| Oct-16-25 | Resumed | Stifel | Buy |
| Oct-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
Nuvalent Shareholders Endorse Board, Pay, and Auditor - The Globe and Mail
Nuvalent Inc (NUVL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Deerfield-linked director entity reports 3,444 Nuvalent (NUVL) RSUs and large holdings - Stock Titan
NUVL stock surges 39% premarket – why is GSK buying this Boston-based oncology company? - MSN
The M&A Class Action Firm Encourages $hareholders to Contact Monteverde Concerning The Merger—PFLC, NUVL, CCRN, and BGMS - GlobeNewswire Inc.
Director at Nuvalent (NUVL) receives 3,444 RSUs in equity grant - Stock Titan
Nuvalent (NUVL) director reports 3,444-share RSU equity award holding 8,590 total - Stock Titan
Nuvalent (NUVL) director granted 3,444 RSUs in new equity award - Stock Titan
Nuvalent (NUVL) director Ron Squarer receives 3,444 RSUs in equity award - Stock Titan
Nuvalent (NUVL) director Anna Protopapas receives 3,444 RSUs in equity grant - Stock Titan
Nuvalent (NUVL) director Oliger awarded 3,444 RSUs, total holdings 7,415 shares - Stock Titan
Nuvalent (NUVL) director Grant C. Bogle receives 3,444 RSU award - Stock Titan
Nuvalent (NASDAQ: NUVL) investors approve board slate, pay and KPMG - Stock Titan
FDA decision: Zidesamtinib by Nuvalent (in 2026) - Coinbase
Are NUVL, DAN, PAYO Obtaining Fair Deals for their Shareholders? - TradingView
Nuvalent Inc (NUVL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Nuvalent Inc (NUVL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nuvalent Inc (NUVL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Nuvalent Inc (NUVL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nuvalent Inc (NUVL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Nuvalent Inc (NUVL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nuvalent Inc (NUVL) Institutional Confidence - TradingKey
Nuvalent Acquisition by GSK Highlights Growing Opportunities in Targeted Oncology Therapies - Streetwise Reports
Responsive Playbooks and the NUVL Inflection - Stock Traders Daily
Here’s What the Acquisition of Nuvalent Means for Nuvation Bio (NUVB) - Insider Monkey
Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK - MSN
Analysts Cut Biopharma Co. to Neutral After Pending US$10.6B Deal - Streetwise Reports
AASTOCKS Financial NewsNuvalent, Inc. (NUVL) - AASTOCKS.com
Novartis taps Orionis for second molecular glue tie-up: Deals Report - BioCentury
GSK agrees to acquire Nuvalent, Inc. - Pennsylvania Business Report -
Halper Sadeh LLC is Investigating Whether DAN, NUVL, SUNE, TMHC are Obtaining Fair Deals for their Shareholders - GlobeNewswire
GSK in talks to buy Nuvalent for more than $9 billion: FT - MSN
GSK To Acquire Nuvalent In Largest Deal In Over A Decade – Merger Arbitrage Mondays (NYSE:GSK) - Seeking Alpha
GSK buys Nuvalent for $10.6 billion in major cancer push - MSN
Nuvalent, Inc. (NUVL) Stock Analysis: Assessing the 3.96% Potential Upside Amidst Biotech Innovation - DirectorsTalk Interviews
Herbert Smith Freehills Kramer advises on the financing for GSK plc's US$10.6 billion acquisition of Nuvalent Inc. - Legal Desire Media and Insights
GSK to Acquire Nuvalent for $10.6 Billion - GuruFocus
The week in pharma: action, reaction and insight – week to June 12, 2026 - The Pharma Letter
Weekend Morning Brew: SpaceX IPO Soars; GSK Acquires Nuvalent - GuruFocus
Patent cliff predators: GSK acquires Nuvalent for $10.6 billion - MSN
Are AVNS, NUVL, XOMA, TBRG Obtaining Fair Deals for their Shareholders? - TradingView
A Quick Look at Today's Ratings for Nuvalent(NUVL.US), With a Forecast Between $124 to $126 - Moomoo
Nuvalent (NUVL) CDO sells 20,000 shares, exercises options - Stock Titan
Nuvalent: 'Hold' On GlaxoSmithKline Acquisition For Selective Tyrosine Kinase Inhibitors - Seeking Alpha
GSK To Acquire Nuvalent for $10.6 Bn - DCAT Value Chain Insights
GSK to acquire Nuvalent for $10.6bn ahead of patent cliff - EMJ
Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion - MSN
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion - MarketBeat
Slaughters, Davis Polk, Ropes line up on GSK’s $10.6bn biotech buy - Non-Billable
Project Nashville: GSK boosts oncology rebuild with $11 billion Nuvalent deal - TradingView
GSK Makes $10.6 Billion Oncology Bet With Nuvalent Acquisition to Accelerate Cancer Expansion (GSK) - Yahoo Finance UK
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):